Why Chinese Bribery Allegations Do Not Put Me Off GlaxoSmithKline Plc

Despite recent adverse news flow detailing alleged bribery by Executives of GlaxoSmithKline plc (LON: GSK) in China, I still think shares are a ‘buy’.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In recent weeks, there have been serious allegations surrounding the alleged bribery of Chinese doctors by pharmaceutical company GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US). Although shares have not been particularly volatile and have not fallen much, the allegations are not to be taken too lightly as China represents a major growth market for the company.

Of course, GlaxoSmithKline initially denied any wrongdoing; stating that it had conducted a thorough internal investigation and found that it had acted within the law. However, since the initial statement the company has admitted that “certain senior executives of GSK China who know our systems well appear to have acted outside of our processes and controls which breaches Chinese law”.

Indeed, it appears as though the company is attempting to blame the alleged misdemeanours on rogue executives as opposed to company policy. Either way, four GlaxoSmithKline executives have been detained, with a further 18 staff also detained in the last day or so.

Should you invest £1,000 in Intel right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Intel made the list?

See the 6 stocks

Of course, the cynic in me thinks that the allegations could be a means of the Chinese government obtaining lower drug prices for its population. I’m not saying they are ‘inventing’ the allegations but GlaxoSmithKline’s second statement could provide an indication as to the overall objective of the Chinese government: “savings made as a result of proposed changes to our operational model will be passed on in the form of price reductions, ensuring our medicines are more affordable to Chinese patients”.

Despite the adverse news flow described above, I still think GlaxoSmithKline is well worth adding to your portfolio. For starters, any wrongdoing is unlikely to be a strategy of the company and is more likely rogue executives, as GlaxoSmithKline seems to be indicating. Furthermore, it would not be a major surprise to learn that executives of other pharmaceutical companies have committed similar wrongdoings, meaning GlaxoSmithKline is unlikely to feel the full force of the Chinese government’s wrath.

In addition, shares yield an impressive 4.4% and trade on a discount to their sector, with shares currently having a price-to-earnings (P/E) ratio of 14.9 versus 16.7 for the healthcare sector.

Of course, you may be looking for other ideas in the FTSE 100 and, if you are, I would recommend this exclusive wealth report which reviews five particularly attractive possibilities.

All five blue chips offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by The Motley Fool as “5 Shares You Can Retire On“.

Simply click here for the report — it’s completely free!

> Peter owns shares in GlaxoSmithKline.

AI Revolution Awaits: Uncover Top Stock Picks for Massive Potential Gains!

Buckle up because we're about to dive headfirst into the electrifying world of AI.

Imagine this: you make a single savvy investment in some cutting-edge technology, then kick back and watch as it revolutionises entire industries and potentially even lines your pockets.

If the mere thought of riding this AI wave excites you and the prospect of massive potential returns gets your pulse racing, then you’ve got to check out this Motley Fool Share Advisor report – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And here’s the kicker – we’re giving you an exclusive peek at ONE of these top AI stock picks, absolutely free! How’s that for a bit of brilliance?

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

At a 52-week low but forecast to rise 73%! Is this growth share the FTSE’s top recovery play? 

This FTSE 100 growth share has taken an absolute beating over the past two years but Harvey Jones says the…

Read more »

Investing Articles

This FTSE 250 share offers a juicy 9.8% yield. Will it last?

This well-known FTSE 250 share has a percentage dividend yield approaching double digits. Should Christopher Ruane add the income share…

Read more »

Investing Articles

Is a £333,000 portfolio enough to retire and live off passive income?

A third of a million pounds can generate a serious amount of passive income, but relying on this sum alone…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing For Beginners

Why FTSE 100 investors should pay attention to ‘Liberation Day’

Jon Smith explains why the upcoming tariff announcement from across the pond could have an impact on the FTSE 100,…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Here’s why Nvidia stock fell 13% in March

The Nvidia stock price rise was looking unstoppable. Should investors now be wondering if the same might be true of…

Read more »

US Stock

It’s ISA deadline week! Here’s my 3-step game plan

Jon Smith tries to calm the hype around the last minute ISA rush to buy stocks and explains why he's…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£10,000 invested in BAE Systems shares at Christmas is now worth…

BAE Systems shares have been surging in the FTSE 100 in 2025, driven higher by the wavering US commitment to…

Read more »

Investing Articles

Up 19% in 2 weeks, can the Tesla share price rebound further?

Tesla's first-quarter delivery numbers came out today. Will they help persuade our writer to invest his money at the current…

Read more »